سعر ارينوتيكان اكتافيس 100 مجم / 5 مل فيال 2022

Irinotecan actavis 100mg/5ml vial: irinotecan 100 mg/5 mL (20 mg/mL) concentrate in a single vial for intravenous infusion after dilution (Actavis > Multipharma).

• First-line therapy of metastatic colorectal carcinoma in combination with 5-fluorouracil and leucovorin.Population: Adults with metastatic colorectal cancerDailyMed (U.S. National Library of Medicine)
• Metastatic colorectal carcinoma that recurred or progressed after initial fluorouracil-based therapy.Population: Adults with metastatic colorectal cancerDailyMed (U.S. National Library of Medicine)

• Dose-limiting toxicities are late diarrhoea and neutropenia/leukopenia; grade 3-4 late diarrhoea occurred in 23-31% with weekly dosing.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to irinotecan or its excipients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - diarrhoea: early diarrhoea with cholinergic symptoms (may be prevented/treated with atropine) and late diarrhoea that can be life-threatening (treat promptly with loperamide; fluids/electrolytes; antibiotics for ileus, fever or severe neutropenia); interrupt and reduce doses for severe diarrhoea.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning - severe myelosuppression; deaths due to sepsis after severe neutropenia have occurred.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increased risk of severe neutropenia in UGT1A1 poor metabolisers (*28/*28, *6/*6, *6/*28).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inducers (phenytoin, phenobarbital, carbamazepine, rifampin, rifabutin, St. John's wort)Substantially reduce irinotecan/SN-38 exposure; substitute non-inducing therapy at least 2 weeks before starting; do not coadminister unless no alternative.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 or UGT1A1 inhibitors (e.g. ketoconazole, clarithromycin, itraconazole, ritonavir, voriconazole)Increase exposure to irinotecan and SN-38; avoid coadministration.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm based on animal data and mechanism (embryofetal mortality and teratogenicity at exposures below human exposure); human data insufficient.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Irinotecan and its metabolites are present in human milk; do not breastfeed during treatment and for 7 days after the final dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Irinotecan: Irinotecan and SN-38 bind topoisomerase I–DNA complex and prevent religation of single-strand breaks.